Early Revisions, Reoperation, and Survivorship of the Exactech Vantage Fixed-Bearing Total Ankle Arthroplasty Implant. Issue 4 (November 2022)

• Record Type: Journal Article
• Authors: Henry, Jensen K.; Rajan, Lavan; Fuller, Robert; Cody, Elizabeth; Ellis, Scott J.; Deland, Jonathan T.; Demetracopoulos, Constantine A.
• Is Part Of: Foot & ankle orthopaedics. Volume 7:Issue 4(2022)
• Publication Date: 2022-11
• Subjects: Ankle Arthritis -- Ankle Arthroplasty -- Ankle Replacement; Foot -- Surgery -- Periodicals; Ankle -- Surgery -- Periodicals; Orthopedics -- Periodicals; 617.584
• DOI: 10.1177/2473011421S00686
• Languages: English
• ISSNs: 2473-0114

Abstract

Category: Ankle Arthritis; Ankle Introduction/Purpose: In the last decade, there has been a rapid increase in the number of total ankle arthroplasties (TAA) performed annually. In addition, multiple novel TAA implants have been introduced onto the market. The Exactech Vantage TAA is a fixed-bearing implant that has been in use since 2016. The tibial component is low-profile with vertically oriented pegs and a cage, while the talus is curved with an anterior flange to prevent subsidence. This study sought to describe the early experience with the Vantage TAA, including reoperation, revision, and radiographic outcomes. Methods: This is a single-center retrospective review of patients who underwent primary TAA using the Vantage Total Ankle (Exactech, Gainesville, FL). Concomitant procedures at the time of index surgery were recorded. Five surgeons contributed patients. Demographics, clinical and operative data, postoperative complications, reoperations, and revisions were collected. Revisions and reoperations were classified by standardized criteria. Radiographs were reviewed by a fellowship-trained foot and ankle surgeon to assess for alignment and peri-implant complications. There were 190 patients included in the study who were all minimum 2 years post-TAR, with mean clinical follow-up of 1.8 years (range: 1-48 months), and mean age 63.3 +- 9.4 years. Ankle arthritis etiologies were 45% post-traumatic (fracture history), 33% instability, 12% primary osteoarthritis, 5% flatfoot, 2% inflammatory arthritis, and 4% other. Thirteen patients (7%) had hindfoot fusion performed previously or at the time of index surgery. Concomitant procedures are shown in Table. Results: Overall implant survivorship was 95.3%. There were 5 intraoperative complications: 4 anterolateral tibial fractures and 1 medial malleolar fracture, all treated with internal fixation at the time of surgery with no further complications. Nine patients (4.8%) underwent revision: 7/9 for tibial loosening, 1 for talar loosening, and 1 for periprosthetic joint infection. Eleven patients (5.8%) underwent reoperation: open gutter debridement (5); irrigation and debridement for superficial infection (4); and bone grafting for cysts (2). Radiographically, preoperative coronal alignment was mean 10.1°, with 87 (49%) ankles with >10° deformity. Three patients had tibial component subsidence that was stable, 3 had stable radiolucency around the tibial component, and 1 had valgus failure through the ankle joint. Nineteen had asymptomatic peri-implant cysts; 16/19 were at the tibia. Conclusion: Short-term results of the Vantage TAA implant demonstrate survivorship of 95.3% at 2 years, which is comparable to similar studies of low-profile, non-stemmed implants. Asymptomatic radiographic complications were primarily cystic changes at the tibial component. Revisions occurred primarily due to loosening of the tibial component. Additional follow-up and multi- institutional support are warranted to further quantify survivorship and risk factors.